Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 4/20 | 0.60 |
| ▸ | SYK | P43405 | 5/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.50 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | ITK | Q08881 | 3/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037531 | 0.93 | GLO1 (0.60) | GLO1SYKGSK3ALRRK2MAPK15 | |
| SCHEMBL3997103 | 0.83 | SYK (0.55) | SYKEGFRITKGRM4 | |
| SCHEMBL4004638 | 0.82 | JAK1 (0.57) | SYKLRRK2EGFRITK | |
| SCHEMBL1076365 | 0.82 | GLO1 (0.68) | GLO1SYKGSK3ALRRK2MAPK15 | |
| SCHEMBL657079 | 0.82 | SYK (0.67) | SYKEGFRITK | |
| SCHEMBL656576 | 0.82 | SYK (0.67) | SYKEGFRITK | |
| SCHEMBL1075107 | 0.80 | GLO1 (0.61) | GLO1SYKGSK3ALRRK2MAPK15 | |
| SCHEMBL19527656 | 0.79 | SYK (0.57) | SYKEGFRITKGRM4BTK | |
| SCHEMBL1039614 | 0.77 | GLO1 (0.83) | GLO1SYKGSK3ALRRK2MAPK15 | |
| SCHEMBL2745583 | 0.77 | SYK (0.51) | SYKEGFRITKGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | claimed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | claimed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | claimed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2011-04-28 | — | — | US | disclosed |
| EP-2276747-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009112490-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098288-A1 | SULFONAMIDES AS ZAP-70 INHIBITORS | ZAP70, SYK, LCK | GLO1 3741/4885SYK 2/4885GSK3A 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.